Hemogenyx Pharmaceuticals Plc (HOPHF)
Hemogenyx Pharmaceuticals Plc operates in the Biotechnology industry of the Healthcare sector, headquartered in London, GL, GB. The stock last traded at $2.33, up 0.00% on the session, giving a market capitalisation of $15.8M. On trailing twelve-month figures it carries a trailing P/E of -2.87, a net margin of 0.0%. Its beta of 1.53 implies it has historically moved more than the broad market.
Hemogenyx Pharmaceuticals Plc is a preclinical-stage biotechnology firm dedicated to discovering, developing, and bringing to market innovative therapies for various blood-related diseases. The company's pipeline includes several promising candidates tailored for the bone marrow/hematopoietic stem cell (BM/HSC) transplant market. These include a CDX bi-specific antibody designed to target relapsed/refractory acute myeloid leukemia (R/R AML), certain forms of acute lymphoblastic leukemia, and myelodysplastic syndrome. This novel approach seeks to condition patients for bone marrow transplants, offering a potential alternative to conventional chemotherapy and/or radiation treatments. Additionally, Hemogenyx is advancing HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to specifically identify and eradicate human AML-derived cells, demonstrated in both in vitro and in vivo studies. Its portfolio also features Human Postnatal Hematopoietic Endothelial Cells, a unique stem cell therapy intended for BM/HSC transplant applications. Established in 2012, the company maintains its headquarters in London, United Kingdom.
Hemogenyx Pharmaceuticals Plc is most often compared with the following Healthcare names: